Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsEventsSponsored PodcastsSponsored VideosWebcastsWhitepaperseBooks
Event Calendar

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Event Calendar
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Kirsten Axelsen

Advertisement

Articles by Kirsten Axelsen

Reducing Prescription Drug Costs for Seniors: The ABCs of ASP for Part D

ByAndrew Parece,Matthew Majewski,Kirsten Axelsen
December 15th 2020

Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.

Advertisement

Latest Updated Articles

  • Reducing Prescription Drug Costs for Seniors: The ABCs of ASP for Part D
    Reducing Prescription Drug Costs for Seniors: The ABCs of ASP for Part D

    December 15th 2020



Advertisement
Advertisement

Trending on PharmExec

1

Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report

2

Ultragenyx Shares Drop Following Failed Phase III Clinical Trial

3

What Moments in FDA’s Review Process Should Patients and Providers be Watching Closely?

4

FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults

5

Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us